All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Pharmaengine Inc., of Taipei, Taiwan, said the Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion recommending the granting of a marketing authorization of Onivyde (irinotecan liposome injection, nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) to treat metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy.